Cargando…

Inhibition of HDAC6 activity in kidney diseases: a new perspective

Histone deacetylase 6 (HDAC6), a cytoplasmic enzyme that plays important roles in many biological processes, is one isoform of a family of HDAC enzymes that catalyse the removal of functional acetyl groups from proteins. HDAC6 stands out from the other members of this family because it almost exclus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ke, Ben, Chen, Yanxia, Tu, Wei, Ye, Ting, Fang, Xiangdong, Yang, Liping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019784/ https://www.ncbi.nlm.nih.gov/pubmed/30134806 http://dx.doi.org/10.1186/s10020-018-0027-4

Ejemplares similares

Dickkopf-3: Current Knowledge in Kidney Diseases
por: Fang, Xiangdong, et al.
Publicado: (2020)

HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease
por: Brijmohan, Angela S., et al.
Publicado: (2018)

Matrix Metalloproteinases-7 and Kidney Fibrosis
por: Ke, Ben, et al.
Publicado: (2017)

Corrigendum: Matrix Metalloproteinase-7 and Kidney Fibrosis
por: Ke, Ben, et al.
Publicado: (2017)

Inhibition of HDAC6 Activity Protects Against Endothelial Dysfunction and Atherogenesis in vivo: A Role for HDAC6 Neddylation
por: Nomura, Yohei, et al.
Publicado: (2021)

LncRNA SNHG1 knockdown inhibits hyperglycemia induced ferroptosis via miR‐16‐5p/ACSL4 axis to alleviate diabetic nephropathy
por: Fang, Xiangdong, et al.
Publicado: (2023)

Roles of interferon regulatory factor 4 in the AKI-CKD transition, glomerular diseases and kidney allograft rejection
por: Song, Jianling, et al.
Publicado: (2023)

Inhibition of HDAC6 With CAY10603 Ameliorates Diabetic Kidney Disease by Suppressing NLRP3 Inflammasome
por: Hou, Qing, et al.
Publicado: (2022)

AKT activation controls cell survival in response to HDAC6 inhibition
por: Kaliszczak, M, et al.
Publicado: (2016)

HDAC6 Inhibition Alleviates Ischemia- and Cisplatin-Induced Acute Kidney Injury by Promoting Autophagy
por: Shi, Lang, et al.
Publicado: (2022)

Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation
por: Lei, Yubin, et al.
Publicado: (2017)

Tubastatin A inhibits HDAC and Sirtuin activity rather than being a HDAC6-specific inhibitor in mouse oocytes
por: Choi, Yun-Jung, et al.
Publicado: (2019)

HDAC inhibitors in kidney development and disease
por: Brilli, Lauren L., et al.
Publicado: (2012)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: King, Jacob, et al.
Publicado: (2021)

HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights
por: Passaro, Eugenia, et al.
Publicado: (2021)

Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity
por: Francelle, Laetitia, et al.
Publicado: (2020)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

The NLPR3 inflammasome and obesity‐related kidney disease
por: Ke, Ben, et al.
Publicado: (2017)

HDAC6 in Diseases of Cognition and of Neurons
por: LoPresti, Patrizia
Publicado: (2020)

MG53: A potential therapeutic target for kidney disease
por: Ke, Ben, et al.
Publicado: (2022)

Inhibition of HDAC6 alleviates cancer-induced bone pain by reducing the activation of NLRP3 inflammasome
por: Hu, Yin-Di, et al.
Publicado: (2023)

Targeted inhibition of endoplasmic reticulum stress: New hope for renal fibrosis
por: Ke, Ben, et al.
Publicado: (2017)

A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
por: Kaliszczak, M, et al.
Publicado: (2013)

Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex
por: Salemi, Louisa M., et al.
Publicado: (2017)

The Role of HDAC6 in Cancer
por: Aldana-Masangkay, Grace I., et al.
Publicado: (2011)

HDAC6 and Ovarian Cancer
por: Haakenson, Joshua, et al.
Publicado: (2013)

HDAC6 regulates IL-17 expression in T lymphocytes: implications for HDAC6-targeted therapies
por: Yan, Bing, et al.
Publicado: (2017)

Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition
por: King, Kristina, et al.
Publicado: (2018)

HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease
por: Braz, Sandra O., et al.
Publicado: (2023)

HDAC6 is associated with the formation of aortic dissection in human
por: Guo, Xian, et al.
Publicado: (2019)

Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo
por: Beconi, Maria, et al.
Publicado: (2012)

α-klotho and anemia in patients with chronic kidney disease patients: A new perspective
por: Xu, Yang, et al.
Publicado: (2017)

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
por: Simões-Pires, Claudia, et al.
Publicado: (2013)

Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells
por: Liu, Jiaqi, et al.
Publicado: (2016)

HTLV-1 inhibits stress granules formation by interacting with the histone deacetylase 6 (HDAC6)
por: Legros, Sébastien, et al.
Publicado: (2009)

HDAC6 Deacetylase Activity Is Critical for Lipopolysaccharide-Induced Activation of Macrophages
por: Yan, Bing, et al.
Publicado: (2014)

Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma
por: Auzmendi-Iriarte, Jaione, et al.
Publicado: (2020)

HDAC6 Inhibition Protects against OGDR-Induced Golgi Fragmentation and Apoptosis
por: Zhang, Jie, et al.
Publicado: (2019)

Inhibition of HDAC6 Attenuates Diabetes-Induced Retinal Redox Imbalance and Microangiopathy
por: Abouhish, Hossameldin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bq0i07n1qsrjrufohri45od62c